Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
NCT05330429 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77
Last updated 2025-07-01
Summary
The goals of this clinical study are to learn more about the safety, tolerability and effectiveness of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).
The primary objectives of this study are: (safety run-in cohort) to evaluate safety and tolerability, and the recommended Phase 2 dose (RP2D) and (randomized cohort) to evaluate the efficacy of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).
Conditions
Interventions
- DRUG
-
Magrolimab
Administered intravenous infusion
- DRUG
-
Administered intravenous infusion
- DRUG
-
Administered intravenous infusion
- DRUG
-
Administered intravenous infusion
- DRUG
-
Administered intravenous infusion
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Gilead Study Director · Gilead Sciences
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-07-08
- Primary Completion
- 2024-06-26
- Completion
- 2024-06-26
- FDA Drug
- Yes
Countries
- United States
- Australia
- Belgium
- Canada
- France
- Germany
- Hong Kong
- Italy
- Puerto Rico
- Spain
Study Locations
More Related Trials
-
Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment
NCT02226289 ·Status: UNKNOWN ·Phase: PHASE2
-
Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer
NCT04230187 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
NCT01996306 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
NCT06540326 ·Status: RECRUITING ·Phase: PHASE2
-
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
NCT00904839 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
NCT00499369 ·Status: TERMINATED ·Phase: PHASE3
-
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
NCT01814501 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT00628810 ·Status: COMPLETED ·Phase: PHASE2
-
Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer
NCT00118261 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
NCT05087992 ·Status: COMPLETED ·Phase: PHASE1
-
Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT04761614 ·Status: COMPLETED ·Phase: PHASE1
-
An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer
NCT01319877 ·Status: COMPLETED
-
Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer
NCT04397601 ·Status: UNKNOWN
-
An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread
NCT03414983 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
NCT00577109 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
NCT03303495 ·Status: UNKNOWN ·Phase: PHASE3
-
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
NCT01418222 ·Status: COMPLETED ·Phase: PHASE2
-
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
NCT00265850 ·Status: COMPLETED ·Phase: PHASE3
-
Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
NCT02305758 ·Status: COMPLETED ·Phase: PHASE2
-
Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer
NCT00571740 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
NCT00778102 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer
NCT00116506 ·Status: COMPLETED ·Phase: PHASE2
-
Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study
NCT07047560 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
NCT00025337 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
NCT05983367 ·Status: TERMINATED ·Phase: PHASE2